Skip to content
PeptideFactSheets
Plain-English comparison

Peptides for weight management: approved versus experimental

A status-first look at approved medicines and experimental peptides discussed for body weight.

By the PeptideFactSheets Editorial Team. Claims are source-checked under our editorial policy; clinician review is identified only when a named reviewer is shown.

The quick overview

The phrase “peptides for weight loss” mixes together approved prescription medicines, research drugs, products approved for a different narrow purpose, and unapproved substances with little human evidence.

Semaglutide, tirzepatide, and liraglutide have products approved for chronic weight management in defined populations. Retatrutide is still in trials. Tesamorelin has a narrow HIV-lipodystrophy indication and is not a general weight-loss medicine.

Side-by-side comparison

Semaglutide
FDA approved for specific usesStrong human evidence for approved uses

Studied for

Type 2 diabetes · Chronic weight management · Cardiovascular outcomes

Tirzepatide
FDA approved for specific usesStrong human evidence for approved uses

Studied for

Type 2 diabetes · Chronic weight management · Obstructive sleep apnea in adults with obesity

Liraglutide
FDA approved for specific usesStrong human evidence for approved uses

Studied for

Type 2 diabetes · Chronic weight management · Cardiovascular outcomes

Retatrutide
In clinical trialsEarly human evidence

Studied for

Obesity and overweight · Type 2 diabetes · Cardiovascular and kidney outcomes

Tesamorelin
FDA approved for specific usesStrong human evidence for approved uses

Studied for

HIV-associated lipodystrophy · Visceral abdominal fat · Metabolic measures

Approved versus investigational

An FDA approval means the agency reviewed evidence for a specific product, population, and use. It does not validate other molecules in the same family or uses outside the label. “In Phase 3” still means investigational.

What researchers are studying

  • Chronic weight management
  • Metabolic health and type 2 diabetes
  • Cardiovascular outcomes
  • Specific fat-distribution conditions

Risks and reasons for caution

  • Eligibility, contraindications, side effects, and required follow-up differ by medicine and person.
  • An approval for diabetes, sleep apnea, or HIV lipodystrophy is not blanket approval for every weight-related goal.
  • Unapproved copies and research products do not undergo the same FDA premarket review.

What remains uncertain

  • Long-term outcomes for newer medicines and newer indications
  • How best to maintain outcomes after treatment changes
  • Whether investigational candidates will earn approval

Questions to ask a healthcare professional

1. Is this exact product FDA approved for this exact use?

2. What outcome matters besides the number on a scale?

3. What risks or other medicines need review?

4. What is the plan for long-term clinical follow-up?

Plain-English takeaway

Status is the first sorting step: approved product for a specific use, investigational drug in a registered trial, or unapproved substance. Those categories should never blur together.

References

  1. 1
    FDA: Drugs@FDA database

    Official source for approval records and current prescribing information.

  2. 2
    ClinicalTrials.gov

    U.S. National Library of Medicine registry of clinical studies.

  3. 3
    FDA: understanding the risks of compounded drugs

    FDA overview of how compounded drugs differ from FDA-approved drugs.